Literature DB >> 31037709

Predictors of mortality and disability in stroke-associated pneumonia.

Rory J Tinker1, Craig J Smith1,2, Calvin Heal3, Joao H Bettencourt-Silva4,5, Anthony K Metcalf6,5,7, John F Potter6,5,7, Phyo K Myint8,9,10.   

Abstract

Whilst stroke-associated pneumonia (SAP) is common and associated with poor outcomes, less is known about the determinants of these adverse clinical outcomes in SAP. To identify the factors that influence mortality and morbidity in SAP. Data for patients with SAP (n = 854) were extracted from a regional Hospital Stroke Register in Norfolk, UK (2003-2015). SAP was defined as pneumonia occurring within 7 days of admission by the treating clinicians. Mutlivariable regression models were constructed to assess factors influencing survival and the level of disability at discharge using modified Rankin Scale [mRS]. Mean (SD) age was 83.0 (8.7) years and ischaemic stroke occurred in 727 (85.0%). Mortality was 19.0% at 30 days and 44.0% at 6 months. Stroke severity assessment using National Institutes of Health Stroke Scale was not recorded in the data set although Oxfordshire Community Stroke Project was Classification. In the multivariable analyses, 30-day mortality was independently associated with age (OR 1.04, 95% CI 1.01-1.07, p = 0.01), haemorrhagic stroke (2.27, 1.07-4.78, p = 0.03) and pre-stroke disability (mRS 4-5 v 0-1: 6.45, 3.12-13.35, p < 0.001). 6-month mortality was independently associated with age (< 0.001), pre-stroke disability (p < 0.001) and certain comorbidities, including the following: dementia (6.53, 4.73-9.03, p < 0.001), lung cancer (2.07, 1.14-3.77, p = 0.017) and previous transient ischemic attack (1.94, 1.12-3.36, p = 0.019). Disability defined by mRS at discharge was independently associated with age (1.10, 1.05-1.16, p < 0.001) and plasma C-reactive protein (1.02, 1.01-1.03, p = 0.012). We have identified non-modifiable determinants of poor prognosis in patients with SAP. Further studies are required to identify modifiable factors which may guide areas for intervention to improve the prognosis in SAP in these patients.

Entities:  

Keywords:  Morbidity; Mortailty; Pneumonia; Stroke; Stroke associated

Year:  2019        PMID: 31037709     DOI: 10.1007/s13760-019-01148-w

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  6 in total

1.  Braden scale for assessing pneumonia after acute ischaemic stroke.

Authors:  Yunlong Ding; Yazhou Yan; Jiali Niu; Yanrong Zhang; Zhiqun Gu; Ping Tang; Yan Liu
Journal:  BMC Geriatr       Date:  2019-10-07       Impact factor: 3.921

2.  Pharmacotherapy Pattern and Treatment Outcomes of Stroke Patients Admitted to Jimma University Medical Center, Ethiopia.

Authors:  Nigatu Beyene; Korinan Fanta; Ramanjireddy Tatiparthi
Journal:  Patient Relat Outcome Meas       Date:  2021-08-07

3.  Effect of transverse sinus variation on the clinical outcomes of atherosclerotic anterior circulation infarction.

Authors:  Lianshuang Wu; Meini Wu; Siou Li; Dan Xu; Yang Jiao; Meilingzi Liu; Changhao Yin
Journal:  Ann Transl Med       Date:  2022-02

4.  Clinical significance of albumin to globulin ratio among patients with stroke-associated pneumonia.

Authors:  Lingli Chen; Minjie Xu; Qiqi Huang; Yuntao Liu; Wenwei Ren
Journal:  Front Nutr       Date:  2022-08-16

5.  In-hospital mortality and its predictors among adult stroke patients admitted in Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia.

Authors:  Maru Admas; Muluken Teshome; Pammla Petrucka; Animut Takele Telayneh; Nakachew Mekonnen Alamirew
Journal:  SAGE Open Med       Date:  2022-09-06

6.  Novel machine learning models to predict pneumonia events in supratentorial intracerebral hemorrhage populations: An analysis of the Risa-MIS-ICH study.

Authors:  Yan Zheng; Yuan-Xiang Lin; Qiu He; Ling-Yun Zhuo; Wei Huang; Zhu-Yu Gao; Ren-Long Chen; Ming-Pei Zhao; Ze-Feng Xie; Ke Ma; Wen-Hua Fang; Deng-Liang Wang; Jian-Cai Chen; De-Zhi Kang; Fu-Xin Lin
Journal:  Front Neurol       Date:  2022-08-25       Impact factor: 4.086

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.